about
Fatigue in type 1 diabetes: A systematic review of Observational studies.Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One YearChronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease.The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of LifeSense of coherence in patients with inflammatory bowel diseaseNeed for standardization in population-based quality of life studies: a review of the current literature.Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study.Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue.Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel DiseaseComparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis.Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population.Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study.IBD patients need in health quality of care ECCO consensus.Patients' perceptions of quality of care and follow-up in inflammatory bowel disease.Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study.Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission.Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort.Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study.Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).Measuring health-related quality of life in non-complicated diabetes patients may be an effective parameter to assess patients at risk of a more serious disease course: a cross-sectional study of two diabetes outpatient groups.Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain.Five-year outcome after gastric bypass for morbid obesity in a Norwegian cohort.Fatigue interference with daily living among patients with inflammatory bowel disease.Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls.Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up.Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms.Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis.Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life.Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort.Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 yearsEffect of phenotype on health care costs in Crohn’s disease: A European study using the Montreal classificationFatigue is not associated with vitamin D deficiency in inflammatory bowel disease patientsPsychometric testing of the Norwegian Diabetes Health Profile (DHP-18) in patients with type 1 diabetesThe Role of Quality of Care in Health-related Quality of Life in Patients with IBDLow colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years
P50
Q30239969-9F6F2950-8524-422B-8EB3-3026411D8566Q35135991-95B6C368-B8E9-49A7-9D45-81E9128EF373Q35200114-312CFAE8-9197-4441-8FFF-FF789245A090Q35725877-6F72CD8F-2201-4E17-AA17-57BB530D7614Q37492485-06AC4C42-9C41-4324-A0F2-8EE8EB300FB3Q37542550-4907C208-0AD8-4BAF-ABFE-1611D30D465FQ37564287-DCC20782-A228-431B-AA09-8F29F1BEE08EQ37991442-0DBD7DB8-81BD-474D-BC97-37E06EB0C063Q38621244-ECDD9981-7EA1-492B-BA5D-449D46E7D5F0Q38838921-3BDCD0B3-03BC-4E95-90E1-58B362261A0BQ39388069-E61F9ED2-454E-464E-BBFA-E0A5C0EF7DB3Q39414345-4BE80D95-9735-4D76-9F05-0344492EF39BQ39749465-4D9C935A-CC80-4BFF-B1CD-8C70093D51E4Q40086288-26987342-F258-47DA-AA42-CDFACADCE5F4Q40243918-8D34E074-B8B5-45B9-A8F9-A22B79F26D92Q40473404-E1D44709-DD67-4C43-AC35-94B40130937BQ40555872-A79FE8A5-A051-46F4-87CA-B8E542A65613Q42040867-9657E56F-0D7C-4640-996E-4337F75E3369Q43829959-F8F974D6-7EC6-46D1-9B1A-16024D20D716Q44024340-F1A9187B-0FB6-4142-88B2-DFCE6AA3E93EQ44197326-67642C98-3C76-4A2D-8703-AB186C1F37D3Q44791207-A74F6320-D1DD-4BF0-830C-421FEE6884B2Q45939575-E51190A0-2487-498D-8C7B-9DCFE9072273Q48069512-7F1159DF-5159-4388-A68D-24C8BC5A9D79Q48141820-6C2DEB8B-7A30-4C45-B286-CD4CCD411ED5Q48181896-8EF55BE7-87D6-48C8-AE5A-C6548F7CDD72Q48297948-F1E78526-FF98-45B7-A997-2E7A6936D4C7Q48471648-FCAB72EF-8CEC-4E4C-8B4B-0FB536E38C7EQ48526441-61C1EEBC-0C27-42DF-97D9-C4C481843D35Q53278023-F45BB96F-BA63-460B-AAD1-8279C870B4E0Q53281331-B8C8BD2A-1572-4F2C-AB31-CC96F6E1CAC4Q53344279-1D60D61F-9457-41BE-85A0-7E3CF0FBD973Q55041194-956B1CB2-EE95-4F48-899F-CC63E1F8DAA2Q55058791-D6B8840A-034E-4518-B10B-353D2193D908Q57265408-17C41D22-6DDF-4E86-9FE3-A9BC64DA191EQ57265416-F63470BE-3EB2-4861-826C-D38177CA0164Q58798104-D536F0F9-54C1-4F5B-B302-245D2DCEB243Q60912323-2B431464-2B51-4D55-9ADC-5C8F61170EA2Q61891397-8AA42B7F-6C78-4B17-BAB9-4FCDFE031910Q79676507-665D4E71-2D35-4A2B-8CC1-CDA9CFF54F3D
P50
description
Noors geneeskunde
@nl
Norwegian physician and researcher
@en
norsk lege og professor i klinisk medisin
@nb
name
Tomm Bernklev
@ast
Tomm Bernklev
@en
Tomm Bernklev
@es
Tomm Bernklev
@fr
Tomm Bernklev
@nb
Tomm Bernklev
@nl
Tomm Bernklev
@sl
Tomm Bernklev
@sq
type
label
Tomm Bernklev
@ast
Tomm Bernklev
@en
Tomm Bernklev
@es
Tomm Bernklev
@fr
Tomm Bernklev
@nb
Tomm Bernklev
@nl
Tomm Bernklev
@sl
Tomm Bernklev
@sq
prefLabel
Tomm Bernklev
@ast
Tomm Bernklev
@en
Tomm Bernklev
@es
Tomm Bernklev
@fr
Tomm Bernklev
@nb
Tomm Bernklev
@nl
Tomm Bernklev
@sl
Tomm Bernklev
@sq
P108
P1015
P214
P1015
P106
P21
P214
P27
P31
P496
0000-0002-9988-2271
P569
1954-01-01T00:00:00Z
P7859
viaf-221566780